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Summary The anti-pan carcinoma monoclonal antibody (MAb) 323/A3, linked to E. coli-derived p-
glucuronidase (GUS) was used to study the tumour-site-selective activation of the prodrug Epirubicin-
glucuronide (Epi-glu). Epi-glu was isolated from the urine of patients treated with Epirubicin (Epi) by reversed
phase chromatography on a silica-C18 column. Epi-glu was stable in human blood and was not converted into
Epi by A2780, MCF-7, or OVCAR-3 cancer cells, despite the presence of intracellular GUS. The stability of
the prodrug was confirmed in BALB/c mice. MAb 323/A3 and GUS were linked through a stable thioether
bond. The conjugate (1:1) was purified by ion exchange and gel filtration chromatography. Binding to target
cells revealed an immunoreactivity of at least 60% and good retention of enzyme activity. A protein dye
(sulforhodamine B) assay was used to analyse cytotoxicity. Epi (IC50 of 0.003-0.2 guM) was 100-1,000 times
more toxic than Epi-glu (IC50 of >20gtM), when cancer cells were exposed for 4 or 24 h to the drugs. The
low cytotoxicity of Epi-glu was most likely due to the reduced cellular uptake rate of the prodrug
(2.7 pmol 106 cells min 1) as compared to that of the parent compound (25 pmol 106 cells min-'). Pretreat-
ment of antigen-positive cells with the 323/A3-GUS conjugate prior to prodrug exposure completely restored
cytotoxicity as a result from hydrolysis of Epi-glu into Epi. Our results demonstrate that the 323/A3-GUS
conjugate can specifically activate the stable non-toxic prodrug Epi-glu at the tumour cell level.
Monoclonal antibodies (MAbs) are successfully being applied
as tumour-selective carriers of various cytotoxic substances,
such as radionuclides, toxins or cytostatic agents. Despite
progress made in anti-tumour efficacy in vitro and in vivo
models, considerable problems remain with these immuno-
conjugates to be effective in the clinic (Haisma, 1991). The
first limitation is the low amount of uptake in human tumour
tissue, which makes it difficult to reach cytotoxic concentra-
tions. A second problem with immunoconjugates of toxins or
cytostatic agents is the release of active drug required at
the tumour site. Lastly, heterogeneity in antigen expres-
sion will result in escape of antigen-negative cells from treat-
ment.
A new approach in MAb-guided therapy is the use of
antibodies to carry enzymes to tumour cells. The enzymes
convert relatively non-toxic prodrugs, which are administered
after the conjugates have localised in tumours, into active
cytotoxic agents. The drug formed can also penetrate into
adjacent tumour cells, thereby avoiding the problem of hetero-
geneity in antigen expression.
The concept of antibody-enzyme mediated chemotherapy
has been described earlier. The few studies carried out in in
vitro as well as in vivo tumour models showed that selective
conversion of prodrug into drug can be obtained at the
tumour site. However, the impact of this treatment cannot
yet be translated to the clinic, because either the enzyme was
abundantly present in many tissues, such as alkaline phos-
phatase (Senter et al., 1988; Haisma et al., 1992), or pro-
karyotic enzymes were used, such as carboxypeptidase-G2
(Bagshawe et al., 1988), penicillin-V-amidase (Kerr et al.,
1990), or P-lactamase (Shepherd et al., 1991; Alexander et al.,
1991). To circumvent the problems of untimely prodrug
activation or the development of an immune response in
patients, the enzyme of choice should preferably be human
and be present in only minimal concentrations in blood and
normal tissues. The glycosidase P-glucuronidase (GUS) is
such an enzyme and occurs in both prokaryotic and
eukaryotic organisms. In mammalian tissues the enzyme is
present in lysosomes and microsomes and blood levels are
low (Dutton, 1966; Fishman, 1970). Therefore, this enzyme
may be a good candidate for conjugation to MAbs to induce
selective activation of prodrugs at the target site.
In our experiments we used the anti-pan carcinoma MAb
323/A3 to prepare the 323/A3-GUS conjugate. This
immunoconjugate was tested for its immunoreactivity,
stability and enzyme activity. We isolated and analysed the
prodrug Epirubicin-glucuronide (Epi-glu) for its stability and
cytotoxicity. We determined whether Epi-glu could be selec-
tively converted into active drug by the 323/A3-GUS con-
jugate bound to the tumour cells.
Materials and methods
Cell lines and cell culture
The human breast cancer cell line MCF-7 (Soule et al., 1973),
and the human ovarian cancer cell lines A2780 (Eva et al.,
1982) and NIH:OVCAR-3 (OVCAR-3, Hamilton et al.,
1984) have been described before. Cells were grown as a
monolayer in Dulbecco's modified Eagle's medium (DMEM)
(Flow Laboratories, Irvine, Scotland) supplemented with
10% heat-activated fetal calf serum (FCS) (Flow), 2 mM
L-glutamine, 50 IU ml-' penicillin and 50 pg ml1 strepto-
mycin (Flow) in a humidified atmosphere containing 5% CO2
at 37°C.
Antibody
Purified murine MAb 323/A3 (Edwards et al., 1986), is an
IgGI and was provided by Professor S.O. Warnaar, Cento-
cor Europe, Leiden, The Netherlands. The antigen recognised
by 323/A3 is a membrane glycoprotein of Mr 43,000 which is
highly expressed in a variety of carcinomas. For Scatchard
analysis, labelling of 323/A3 with 1251 was performed with
iodogen according to the one vial method (Haisma et al.,
1986). The specific activity of 323/A3 after iodination was
approximately 10 mCi mg-' antibody. Precipitation with
10% trichloroacetic acid (TCA) indicated that >95% of the
radioactivity was bound to protein in the final preparations.
The number of binding sites and affinity constant of 1251I
labelled 323/A3 were determined with glutaraldehyde-fixed
MCF-7, A2780 or OVCAR-3 cells according to Lindmo et
al. (1984).
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P-Glucuronidase
GUS from E. coli K12 was purchased from Boehringer
(Mannheim, Germany). The enzyme activity was measured
with p-nitrophenyl-,-D-glucuronide (1 mM in PBS). Samples
were incubated with substrate for 30 min at 37°C. The reac-
tion was stopped by the addition of 1 M NaOH and the
absorbance at 405 nm was read. The specific activity of the
enzyme preparation appeared to be 70 U mg-' (pmol min 1).
The stability of GUS was measured in tissue culture medium
(MEM or DMEM, with 10% FCS) and in FCS or human
serum at 37°C. GUS (1 .g ml1 final concentration) was
added to the different media and sera, and samples were
taken at 0 min, 30 min, 4 h, 24 h, 48 h and 72 h.
323/A3-GUS conjugate
MAb 323/A3 and GUS were conjugated using a thioether
linkage. GUS was first purified by gel filtration on a
Superose 6 column (Pharmacia, Woerden, The Netherlands)
with PBS. The fractions were analysed for GUS activity.
Enzyme-containing fractions were pooled and stored at 4°C
until use. Coupling via the 4 thiol groups per molecule
already present in GUS resulted in a low conjugation
efficiency. Therefore, extra thiol groups were introduced.
Unfortunately, the use of N-succinimidyl 3(2-pyridyldithio)
propionate (SPDP, Pharmacia) in this procedure induced a
dramatic drop in enzyme activity, which was presumably
caused by cross-linking with the native thiol groups.
Iminothiolane-thiolated GUS showed minimal loss ofenzyme
activity. Therefore, conjugates were prepared as follows. The
enzyme was treated with a 100-fold excess of iminothiolane
(Pierce, Oud-Beierland, The Netherlands) in PBS with 1 mM
EDTA for 45 min at room temperature. This resulted in the
addition of approximately 4 thiol groups per molecule with-
out affecting the enzyme activity. MAb 323/A3 was reacted
with a 10-fold excess of N-succinimidyl 4-(N-maleimido-
methyl) cyclohexane-l-carboxylate (SMCC, Pierce) to intro-
duce approximately two maleimide groups per molecule.
Enzyme and antibody were mixed at a 1:2 (mol/mol) ratio
and incubated overnight at 4°C. The mixture containing
GUS, 323/A3, and the conjugate was passed over a Mono Q
column (Pharmacia) in PBS to remove unconjugated 323/A3.
A gradient of PBS-PBS with 0.5 M NaCl was used to elute
the enzyme and conjugate. Enzyme-containing fractions were
concentrated and then loaded on a Superose 6 column (Phar-
macia) to remove free GUS.
The enzyme activity and the stability of the conjugate in
vitro was measured as described for GUS alone. Immuno-
reactivity ofthe conjugate was calculated from the binding of
0.2,Lgml-' 323/A3-GUS to various concentrations of
glutaraldehyde-fixed OVCAR-3 cells. In this assay, enzyme
activity was used to measure the percentage of binding to
infinite antigen excess (Lindmo et al., 1984).
Conjugate internalisation and shedding were evaluated by
FACS analysis. MCF-7 and OVCAR-3 cells were incubated
first with conjugate (5jigml-') at 4°C for 1 h. Thereafter,
aliquots of cells were fixed with 1% paraformaldehyde in
MEM with 10% FCS at 37°C for time points up to 24 h. The
cells were then washed and incubated with FITC-conjugated
rabbit anti-mouse IgG (Dakopatts, Denmark) for 45 min.
Fluorescence was measured with a FACs'ar+ (Becton Dickin-
son).
Stability ofthe conjugate when bound to the cell surface of
tumour cells was measured as follows. Cells were incubated
with conjugate as described for FACS analysis. After
washing with PBS, the cells were divided into two portions
for each cell line. For one of each set of aliquots the enzyme
activity bound to the cells was measured immediately, as
described for GUS alone. The enzyme activity of the other
aliquots was determined after an incubation in MEM at 37°C
for 24 h. The enzyme activity measured immediately and
after 24 h were compared to determine the stability of the
conjugate when bound to cells.
Epirubicin-glucuronide
Epi-glu (Figure 1) was isolated from urine (collected for 4 h
after administration of the drug) from patients treated with
Epi (75-120 mgm-2 i.v.). The urine was filtered through
paper and the pH was adjusted to 2.5 with 12 M phosphoric
acid. Methanol was added to a final concentration of 20%.
Epi-glu was purified on a silica-C18 column (15 cm x 1.6 cm
I.D., 0.03LLm; Serva, Heidelberg, Germany) with 0.15 mM
sodium dihydrogen phosphate buffer, 2 mM triethylamine
(pH 3.5)-acetonitrile (2:1, v/v). Fractions containing Epi-glu
were loaded on C18 cartridges (Seppack, Millipore, Milford,
MA) and eluted with 2 ml of methanol. The solvent was then
evaporated at 40°C under a stream of nitrogen. Purity of
Epi-glu and the formation of Epi after hydrolysis by GUS
were measured by HPLC using a silica-C18 column
(4.6 x 100 mm, 3 lm CP; MicroSpher, Chrompack, Middel-
burg. The Netherlands) and an isocratic eluent which
consisted of 2 mM triethylamine in 20mM NaH2PO4
(pH 4.0)-acetonitrile (2:1, v/v) at a flow rate of 1 ml min-'.
Before each analysis, samples were diluted in 0.1 M phos-
phoric acid, 7.5% acetonitrile in PBS to precipitate serum
proteins. The eluate was analysed with a fluorescence detec-
tor using an excitation wavelength of 480 nm and an emis-
sion wavelength of 580 nm. Each run included standards of
Epi and Epi-glu.
The kinetics of the hydrolysis of Epi-glu by GUS was
determined at concentrations of 0.1 to 100 lIM of Epi-glu in
PBS by incubating with enzyme (0.1 U ml-') for 30 min at
37°C. Hydrolysis was followed by HPLC analysis. Peak areas
were used to calculate the concentrations of Epi-glu and Epi.
Plots of velocity (v) vs the ratio of (v) and substrate concen-
tration (s) (Eady-Hofstee plot) were used to calculate Vmax
and Km.
The stability of Epi-glu in vitro was studied under various
conditions. Epi-glu (10jLM final concentration) was added to
FCS, human blood or serum, tissue culture medium (MEM
or DMEM, with 10% FCS) or to A2780, MCF-7 and
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Figure 1 Molecular structure of Epirubicin-glucuronide.476 H.J. HAISMA et al.
OVCAR-3 cells (106ml') in tissue culture medium (DMEM
with 10% FCS). At different time intervals (Oh, 4 h and
24 h) samples were taken and analysed by HPLC for the
presence of Epi-glu and derivatives.
For in vivo stability studies, Epi-glu (2.5 mgkg-') was
injected into the retro-orbital vein of six female BALB/c mice
(8 weeks of age). After 10 min, 30 min, 1 h, 2 h, 4 h and 24 h,
mice were bled under ether anaesthesia. Thereafter, heart and
liver were collected and stored at - 20°C until HPLC
analysis.
In vitro cytotoxicity
First, the cellular uptake ofEpi and Epi-glu were determined.
Cells were harvested from tissue culture flasks with EDTA in
PBS. Aliquots of 106 cells in 100gl were incubated with Epi
or Epi-glu (1OlM) in DMEM at 37°C for up to 24 h. At
different time points, these aliquots were washed with ice-
cold PBS. A sample of the cells was examined by fluore-
scence microscopy to determine the cellular localisation of
the drugs. The remaining cells were solubilised in 0.1 M phos-
phoric acid, 7.5% acetonitrile in PBS and the amount of the
anthracyclines present in the cells was measured by
fluorescence detection (excitation 480 nm, emission 560 nm).
Cells spiked with Epi and Epi-glu were used as standards.
The cytotoxic effects of Epi and Epi-glu were compared by
measuring cell growth with a protein dye stain (Maas et al.,
1991). Cells were harvested with trypsin/EDTA in PBS and
plated at 20,000 cells/well (106ml-'). Drugs or prodrug in
MEM was added to provide a final concentration range of
0.001 to 20 4M. After incubation for 4 h or 24 h fresh
medium was added (DMEM) and the cells were grown for
another 72 h. Cells were fixed with 5% ice-cold TCA, washed
with water and stained with 0.4% sulforhodamine B dis-
solved in 1% (v/v) acetic acid. After rinsing with 1% acetic
acid the plates were air-dried and the bound dye was
solubilised with 10 mm unbuffered Tris. The absorbance at
540 nm was determined and was linear with cell concentra-
tions up to 500,000 cells/well. The effect of the conjugate on
the cytotoxicity of Epi-glu was measured by pretreating the
cells with 323/A3-GUS at 5figml-'. Cells pretreated with
conjugate at 5lagml-' plus excess antibody at I00 lgml-' or
with buffer alone served as controls. After incubation for 1 h
at 4°C, cells were washed with PBS, plated, and treated with
drug as described above.
Results
Antibody, enzyme andconjugate
The three cell lines A2780, MCF-7, and OVCAR-3 were
characterised with regard to their antibody-binding sites for
MAb 323/A3. A2780 cells showed no specific binding with
323/A3, whereas 3.4 x 105 and 2.5 x 105 binding sites were
present on MCF-7 and OVCAR-3 cells, respectively. Scat-
chard plots revealed a high affinity of 323/A3 for its antigen
with Ka= l x 1010 L/M.
In initial studies it was found, that GUS activity rapidly
decreased in DMEM tissue culture medium. Therefore, the
stability of GUS in different tissue culture media and in sera
was investigated. GUS activity rapidly declined in DMEM,
with <1% remaining at 24 h. GUS was more stable in
MEM with 50% loss of activity within 24 h. A 50% loss of
activity was also observed in FCS or in human serum after
24 h. In the experiments to assess the effect of the 323/A3-
GUS conjugate on the toxicity of Epi-glu, MEM was used
for the initial 24-h incubation period of the cells.
GUS was covalently linked to 323/A3 through a stable
thioether bond. The overall protein yield of monomeric con-
jugate (1:1) after purification was approximately 10%. The
conjugate retained >90% GUS activity (final specific
activity 45 Umg-') and showed no loss in binding capacity
towards target cells as measured with p-nitrophenyl-p-D-
glucuronic acid. The immunoreactivity measured on
OVCAR-3 cells was at least 60%.
To be effective, internalisation of the MAb-enzyme con-
jugate by the target cells should be minimal. Therefore, we
analysed the stability of the conjugate after binding to cells
by both fluorescence analysis and by measuring cell surface-
bound enzyme activity. After incubation for 24 h MAb 323/
A3 remained at the cell surface in tissue culture medium at
37°C, whereas 323/A3-GUS showed a 20% decrease in cell
surface expression when measured by flow cytometry. The
enzyme activity present on the cell surface after incubation
for 24 h remained at approximately 90%, indicating the
stability of the conjugate when bound to the cell surface.
Epirubicin-glucuronide
The anthracyclines in the urine of patients treated with Epi
consisted of approximately 60% Epi, 35% Epi-glu and 5%
other metabolites of Epi (mainly epirubicinol and epi-
rubicinol-glucuronide). Purification of Epi-glu with a silica
C-18 column resulted in a yield of 60% (approximately 1 mg
per patient). The final preparation contained <5% impuri-
ties, mainly epirubicinol-glucuronide, but no detectable Epi
(data not shown). The stability of Epi-glu in vitro was deter-
mined with A2780, MCF-7, and OVCAR-3 cancer cells and
with human blood or serum because both cells and serum
contain low levels of P-glucuronidase. Cells exposed to Epi-
glu in vitro for 4 h or 24 h did not convert Epi-glu into Epi,
despite the presence of intracellular GUS. Epi-glu incubated
with whole blood was stable and less than 5% degradation
was detectable after 24 h.
The in vivo pharmacokinetics and stability of Epi-glu were
examined in BALB/c mice. No Epi could be detected in the
blood, heart or liver, indicating the stability of the prodrug
for at least 24 h. Epi-glu cleared from the blood with a t4a of
7 min at a tb of 77 min. After administration of 2.5 mgkg-'
i.v. Maximum tissue levels of Epi-glu were 3;M for blood,
0.06 nmol g' for heart and 0.4 nmolgI for liver. Final
half-lives in heart and liver were the same as for blood
(Figure 2).
The kinetics of the conversion of Epi-glu into Epi by GUS
was determined by HPLC analysis. The kinetic constant Km
was calculated from the slope of the Eady-Hofstee plot
visualised in Figure 3 and was found to be 10liM. The
maximum velocity Vmax was calculated from the intercept at
the ordinate and was 39 nmol minmg-' GUS.
In vitro cytotoxicity
The cellular accumulation of Epi and Epi-glu were compared
as the more polar Epi-glu was expected to have a reduced
cellular uptake. Cellular Epi concentrations increased rapidly
with an initial uptake rate of 25 pmollO-6 cellsmin'.
Indeed, Epi-glu accumulation was much slower with an
uptake rate of 2.7pmol 106cellsmin'1. This resulted in
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Figure 2 Concentration-time curves of Epi-glu in BALB/c mice
after injection of 2.5 mgkg-' i.v.; plasma (0), liver (-), heart
(A).
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Table I IC50 of Epi and Epi-glu after 24-h exposure
A2780a OVCAR-3a MCF-7a
Epi 0.003 ± 0.001 0.2 ± 0.1 0.1 ± 0.1
Epi-glu >20 >20 >20
Epi-glu +conj.b 0.5 0.2 0.4 0.1 0.5 0.3
Epi-glu + conj. + MAbC 0.3 ± 0.2 3.0 ± 0.5 2.5± 1.0
'IC50 expressed in llM ± s.d., results from three separate
experiments. bCells pretreated with 323/A3-GUS conjugate at
S fig ml-1. cCells pretreated with 323/A3-GUS conjugate at 5 pgml',
with excess 323/A3 at 100i,gml-'.
v/s
Figure 3 Eady-Hofstee plot for enzyme kinetics of the hydrolysis
of Epi-glu by GUS.
concentrations of 4 nmol I0- cells for Epi and
1 nmol 10-6 cells for Epi-glu at 24 h (Figure 4). Cells treated
with Epi or Epi-glu were also examined by fluorescence
microscopy before solubilisation. Cells incubated with Epi
showed strong fluorescence of the drug in the nucleus,
whereas Epi-glu staining was restricted to the cell membrane.
The cytotoxic effects of Epi and Epi-glu were determined
by measuring cell growth after drug exposure for 24 h. A2780
cells were most sensitive to Epi with an IC50 of 0.003 gM.
OVCAR-3 and MCF-7 cells were approximately 10-fold less
sensitive to Epi, with an IC50 of 0.2 ;M and 0.1 mM, respec-
tively. Epi-glu showed poor toxicity towards the three cell
lines with an IC50 >20gtM and was thus 100-1,000 times
less toxic than Epi (Table I). Pretreatment of MCF-7 or
OVCAR-3 cells with 323/A3-GUS prior to Epi-glu exposure
resulted in an IC50 similar to that for Epi (Figure 5). Even a
4-h drug exposure time was sufficient to completely reverse
activity of Epi-glu to Epi (data not shown). Co-incubation
with excess cold antibody (100 pgml-') resulted in an almost
complete blockade of binding of the conjugate (2% binding)
and a much smaller shift in the reversal of Epi-glu to Epi.
For antigen-negative A2780 cells pretreatment with the con-
jugate had litle effect on Epi-glu cytotoxicity.
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Discussion
Several enzymes conjugated to MAbs are currently being
investigated for the selective activation of prodrugs at the
tumour site. The present study indicates that P-glucuronidase
may be used to activate glucuronidated drugs. We showed
that the prodrug Epi-glu is 100-1,000 times less toxic than
Epi and can be completely hydrolysed by the GUS-MAb
conjugate bound to tumour cells into the active cytotoxic
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Figure 4 Cellular uptake of Epi (0) and Epi-glu (@) at 10gM
by OVCAR-3 cells, as measured by fluorescence after solubilisa-
tion of the cells.
Figure 5 Growth inhibition of Epi (0), Epi-glu (0), and Epi-
glu after preincubation with 323/A3-GUS conjugate (U). Cells
were exposed to the drugs for 24 h. Growth was measured with
sulforhodamine B at 72h.
drug Epi. Even at non-saturating concentrations, probably
found in the in vivo situation, a remarkable cytotoxic effect
could be obtained in antigen-positive tumour cells.
Epi is an active anti-tumour agent in patients with breast
cancer, lymphomas, ovarian cancer, and soft-tissue sarcomas
(Cersosimo & Ki Hong, 1986). Epi-glu is a naturally occur-
ring metabolite in patients treated with Epi and the pharma-
cokinetics are well known (Mross et al., 1988). We used
Epi-glu as a model prodrug. Our hypothesis that this pro-
drug would be less toxic than Epi, but upon hydrolysis,
would be as active as Epi was confirmed. We demonstrated
that the low cytotoxicity of Epi-glu was caused by its
decreased cellular uptake. Epi-glu was stable in serum and in
vivo in BALB/c mice. Epi-glu was not hydrolysed by tumour
cells, but complete activation occurred by 323/A3-GUS
bound to the tumour cells. These characteristics contrast
favourably with other prodrugs used for antibody-directed
enzyme targeting. For instance, etoposide phosphate (Senter
et al., 1988; Haisma et al., 1992) and p-N-bis (2-chloroethyl)
aminobenzoyl glutamic acid derivative (Bagshawe et al.,
1988) were less stable and p-di-2-chloroethylaminophenol-p-
D-glucuronide (Roffier, 1991) was only 10-times less toxic
than the parent compound.
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The enzyme selected for conversion ofthe prodrug into the
active drug, should preferably be of human origin to
minimise an antibody response in patients. This makes the
use of prokaryotic enzymes such as carboxypeptidase (Bag-
shawe et al., 1988), penicillin-V-amidase (Kerr et al., 1990)
and ,-lactamase (Shepherd et al., 1991; Alexander et al.,
1991) less attractive. Also, the enzyme should be active at a
pH found in the extracellular space of tumours, which is acid
to near neutrality (Tannock & Rotin, 1989). This will reduce
the possibility to explore alkaline phosphatase for prodrug
activation. The latter enzyme is also abundantly present in
blood and normal tissues, which will lead to the untimely
activation of the prodrug. Recently, Haenseler et al. (1992)
have reported on the use of bovine pancreas carboxypep-
tidase A to activate the prodrug methotrexate-a-alanine. The
prodrug was approximately 150 times less toxic than the
drug, but was not completely hydrolysed by the enzyme. This
resulted in only a 6-fold difference in cytotoxicity for cells
treated with the prodrug alone as compared to treatment
with the prodrug combined with the antibody-enzyme con-
jugate. Unfortunately, no data were presented on the in vivo
stability of the prodrug or the enzyme.
We used GUS from E. coli because it was readily avail-
able. The human enzyme may be less efficient, because its pH
optimum is 5.4 as compared to 6.8 for E. coli-derived GUS.
Also, the human enzyme has a lower turnover rate (Dutton,
1966; Fishman, 1970). In fact, the Vmax of 39 nmol
min-' mg-' of E. coli-derived GUS is,low as compared to
that for the synthetic substrate p-nitrophenyl-p-D-
glucuronide. Therefore, alternative routes for glucuronidation
of the Epi molecule or other cytostatic agents should be
explored, which could even lead to efficient hydrolysis by
GUS from human origin.
The human GUS enzyme should be less immunogenic in
patients. For ultimate treatment of cancer based on
antibody-enzyme prodrug targeting the group of Bosslet et
al. (1992) has produced a fusion protein by molecular
biology techniques consisting of human GUS and the
humanised Fab' of MAb BW431/26. Studies are in progress
to evaluate the efficiency of this conjugate in the hydrolysis
of Epi-glu in vitro as well in vivo.
In our experiments we have demonstrated the potential
usefulness of E. coli-derived GUS as an enzyme to be used
for specific prodrug activation after conjugation to MAbs.
Further studies will include the validation of the concept in
tumour-bearing animals and will mainly focus on the value
of human GUS in this new treatment approach.
References
ALEXANDER, R., BEELEY, N.R.A., O'DRISCOLL, M., O'NEILL, F.P.,
MILLICAN, T.A., PRATT, A.J. & WILLENBROCK, F.W. (1991).
Celhalosporin nitrogen mustard cabamate prodrugs for
'ADEPT'. Tetrahedron Lett., 32, 3269-3272.
BAGSHAWE, K.D., SPRINGER, C.J., SEARLE, F., ANTONIW, P.,
SHARMA, S.K., MELTON, R.G. & SHERWOOD, R.F. (1988). A
cytotoxic agent can be generated selectively at cancer sites. Br. J.
Cancer, 58, 700-703.
BOSSLET, K., CZECH, J., LORENZ, P., SEDLACEK, H.H., SCHUER-
MANN, M. & SEEMAN, G. (1992). Molecular and functional char-
acteristics of a fusion protein suited for specific prodrug activa-
tion. Br. J. Cancer, 65, 234-238.
CERSOSIMO, R.J. & KI KONG, W. (1986). Epirubicin: a review of the
pharmacology, clinical activity, and adverse effects of an
adriamycin analogue. J. Clin. Onc., 4, 425-439.
DUTTON, G.J. (1966). Glucuronic Acid Free and Combined. Academic
Press: New York, London.
EDWARDS, D.P., GRZYB, K.T., DRESSLER, L.G., MANSEL, R.E.,
ZARA, D.T., SLEDGE, G.W. & McGUIRE, W.L. (1986). Monoclonal
antibody identification and characterization of a Mr 43,000 mem-
brane glycoprotein associated with human breast cancer. Cancer
Res., 46, 1306-1311.
EVA, A., ROBBINS, K.C., ANDERSEN, D.R., SCINIVASAN, A.,
TRONICK, S.R., REDDY, E.P., ELLMORE, N.W., GALEN, A.T.,
LAUTENBERGER, J.A., PAPAS, T.S., WESTIN, E.H., WONG-
STAAL, F. & GALLO, R.C., AARONSON, S.A. (1982). Cellular
genes analogues to retroviral onc genes are transcribed in human
tumour cells. Science, 295, 116-118.
FISHMAN, W.H. (1970). Metabolic Conjugation and Metabolic Hy-
drolysis. Academic Press: New York, London.
HAISMA, H.J., HILGERS, J. & ZURAWSKI, V.R. Jr (1986). lodination
of monoclonal antibodies for diagnosis and radiotherapy using a
convenient one vial method. J. Nucl. Med., 27, 1890-1895.
HAISMA, H.J. (1991). Monoclonal antibodies. In The Nude Mouse in
Oncology Research. Boven, E. & Winograd, B. (ed.). CRC Press:
Boca Raton, Fla, p. 231-246.
HAISMA, H.J., BOVEN, E., VAN MUIJEN, M., DE VRIES, R. & PINEDO,
H.M. (1992). Analysis of a conjugate between an anti-
carcinoembryonic antigen monoclonal antibody and alkaline
phosphatase for specific activation of the prodrug etoposide-
phosphate. Cancer Immunol. Immunother., 34, 343-348.
HAMILTON, T.C., YOUNG, R.C., LOUIE, K.G., BEHRENS, B.C.,
McKOY, W.M., GROTZINGER, K.R. & OZOLS, R.F. (1984). Char-
acterization of a xenograft model of human ovarian carcinoma
which produces ascites and intraabdominal carcinomatosis in
mice. Cancer Res., 44, 5286-5290.
HAENSELER, E., ESSWEIN, A., VITOLS, K.S., MONTEJANO, Y.,
MUELLER, B.M., REISFELD, R.A. & HUENNEKENS, F.M. (1992).
Activation of methotrexate-a-alanine by carboxypeptidase A-
monoclonal antibody conjugate. Biochemistry, 31, 891-897.
KERR, D.A., SENTER, P.D., BURNETT, W.V., HIRSCHBERG, D.L.,
HELLSTROM, I. & HELLSTROM, K. (1990). Antibody-penicillin-
V-amidase conjugates kill antigen positive cells when combined
with doxorubicin phenoxyacetamide. Cancer Immunol. Immuno-
ther., 31, 202-205.
LINDMO, T., BOVEN, E., CUTTITTA, F., FEDORKO, J. & BUNN, P.A.J.
Jr (1984). Determination of the immunoreactive fraction of
radiolabeled monoclonal antibodies by linear extrapolation to
binding at infinite antigen excess. J. Immunol. Methods, 72,
77-82.
MAAS, I.W.H.M., BOVEN, E., PINEDO, H.M., SCHLUPER, H.M.M. &
HAISMA, H.J. (1991). The effects of y-interferon combined with
5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and
antigen expression in a panel of human colorectal cell lines. Int.
J. Cancer, 48, 749-756.
MROSS, K., MAESSEN, P., VAN DER VIJGH, W.J.F., GALL, H., BOVEN,
E. & PINEDO, H.M. (1988). Pharmacokinetics and metabolism of
epidoxorubicin and doxorubicin in humans. J. Clin. Onc., 6,
517-526.
ROFFLER, S.R., WANG, S., CHERN, M., YEH, M.Y. & TUNG, E.
(1991). Anti-neoplastic glucuronide prodrug treatment of human
tumor cells targeted with a monoclonal antibody-enzyme con-
jugate. Biochem. Pharmacol., 42, 2062-2065.
SENTER, P.D., SAULNIER, M.G., SCHREIBER, G.J., HIRSCHBERG,
D.L., BROWN, J.P., HELLSTROM, I. & HELLSTROM, K.E. (1988).
Anti-tumor effects of antibody-alkaline phosphatase conjugates in
combination with etoposide phosphate. Proc. Nati Acad. Sci.
USA, 85, 4842-4845.
SHEPHERD, T.A., JUNGHEIM, L.N., MEYER, D.L. & STARLING, J.
(1991). A novel targeted delivery system using a cephalosporin-
oncolytic prodrug activated by an antibody-p-lactamase con-
jugate for the treatment of cancer. Bioorg. Med. Chem. Lett., 1,
21-26.
SOULE, H.D., VAZQUEZ, J., LONG, A., ALBERT, S. & BRENNAN, M.
(1973). A human cell line from a pleural effusion derived from a
breast carcinoma. J. Natl Cancer Inst., 51, 1409-1415.
TANNOCK, I.F. & ROTIN, D. (1989). Acid pH in tumors and its
potential for therapeutic exploitation. Cancer Res., 49,
4373-4384.